Pre Exposure Prophylaxis News and Research

RSS

Understanding factors influencing PrEP prescribing for adolescents

HIV pre-exposure prophylaxis (PrEP), a daily dose of two medications meant to prevent HIV infection in high-risk people, has changed public health dramatically in recent years.

14 Nov 2023

Study launched to test a vaginal film that slowly dissolves over the course of 30 days

A vaginal film designed to slowly dissolve over the course of 30 days is being put to the test for the first time in a study launched this week that aims to determine its feasibility and acceptability as a potential HIV prevention method for women.

2 Nov 2023

NIH awards $2.1 million to UCLA to end the HIV epidemic

The National Institutes of Health (NIH) has granted $2.1 million to UCLA's Center for HIV Identification, Prevention, and Treatment Services (CHIPTS) and the UCLA-CDU Center for AIDS Research (CFAR) to support four research projects and an implementation science consultation hub.

2 Nov 2023

Generic PrEP use could reduce new HIV acquisitions, save lives among young men who have sex with men

Anne Neilan, MD, a physician-scientist in the division of Infectious Diseases at Massachusetts General Hospital is the senior author of a recently published paper in Clinical Infectious Diseases, Daily Oral HIV Pre-exposure Prophylaxis Among Young Men Who Have Sex With Men in the United States: Cost-Saving at Generic Drug Price.

12 Oct 2023

Amsterdam's H-TEAM initiative on track to eradicate HIV with groundbreaking city-centered approach

Amsterdam's H-TEAM initiative has achieved a significant reduction in HIV infections from 2010 to 2022 using a city-centered approach. By combining treatments, including testing, pre-exposure prophylaxis, and stakeholder collaboration, the city has surpassed the UNAIDS 95-95-95 target and is on track to potentially eliminate HIV entirely in the near future.

9 Oct 2023

Record uptake of HIV testing among gay, bisexual, and other men who have sex with men

2022 saw the highest ever uptake of HIV testing among gay, bisexual, and other men who have sex with men (GBMSM), with diagnoses in this group continuing to fall, according to the latest HIV surveillance update for the UK.

3 Oct 2023

Comparing HIV PrEP medications: Study explores hypertension risk in adults on TAF vs. TDF

The risk of hypertension and statin initiation in adults starting Human Immunodeficiency Virus Pre-exposure prophylaxis.

13 Sep 2023

Global case series uncovers Mpox resurgence among previously infected or fully vaccinated individuals

Researchers elucidated monkeypox's (mpox) epidemiological and clinical features.

8 Sep 2023

Study reveals substantial gap in PrEP access in more than one-third of New England colleges and universities

Young gay, bisexual, and other men who have sex with men (MSM), accounted for 80% of new HIV infections among youth ages 13–24 in 2018 and represents a priority population for HIV prevention.

24 Jul 2023

Could neutralizing SARS-CoV-2 monoclonal antibodies pre-exposure prophylaxis be cost-effective in a population at risk for severe COVID-19?

A recent study evaluated the cost-effectiveness of monoclonal antibodies as pre-exposure prophylaxis (PrEP) for COVID-19.

11 Jul 2023

Antiretroviral treatment efficiently suppresses penile HIV replication

Of the 38 million people worldwide living with HIV, approximately 700,000 are newly infected men, primarily via sexual transmission.

12 Jun 2023

Real-world assessment of JYNNEOS vaccine effectiveness during the 2022 mpox outbreak in the US

A recent study published in Morbidity and Mortality Weekly Report estimated the efficacy of the JYNNEOS vaccine against mpox.

22 May 2023

Understanding the adverse events profile of MVA-BN vaccine for Mpox

Researchers evaluated adverse events following the Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccination for mpox.

10 May 2023

Post-exposure doxycycline approach leads to two-thirds reduction in STI incidence

The oral antibiotic doxycycline prevented the acquisition of sexually transmitted infections (STIs) when tested among men who have sex with men (MSM) and transgender women who took the medication within 72 hours of having condomless sex, according to findings published today in the New England Journal of Medicine.

6 Apr 2023

Study examines parental concerns of their sexual and gender minority adolescents using PrEP

Since its approval in 2012, HIV pre-exposure prophylaxis, or PrEP, has shown promise in reducing HIV infection rates by preventing infection in high-risk HIV-negative people.

2 Mar 2023

Use of dapivirine vaginal ring during third trimester of pregnancy poses no safety concerns

A vaginal ring containing the antiretroviral drug dapivirine posed no safety concerns when used in the third trimester of pregnancy, according to results to date from the first study of the dapivirine ring during pregnancy and one of only a few studies of an HIV prevention product in pregnant cisgender women.

20 Feb 2023

Doxycycline taken after sex does not prevent bacterial STIs among cisgender women

Researchers from the University of Washington (UW), Kenya Medical Research Institute (KEMRI), and Hennepin Healthcare Research Institute (HHRI) announced results at CROI from a clinical trial demonstrating that doxycycline taken after sex does not prevent bacterial sexually transmitted infections (STIs) – chlamydia or gonorrhea – among cisgender women.

20 Feb 2023

HIV prevention model in Zambian prisons may be extended to other criminal justice facilities

A recent study performed in Zambia by University of Maryland School of Medicine's Institute of Human Virology researchers found that high uptake of HIV preventative medicine, known as pre-exposure prophylaxis (PrEP), is possible in prison populations with adequate resources and support from the criminal justice health system.

16 Feb 2023

New formulation can provide up to six months of full protection against HIV

For people at high risk of contracting HIV, missing doses of their daily HIV prevention pills can have big consequences. In some cases, missing a pill can lead to lack of protection against the virus.

9 Feb 2023

Side-effects and costs are important issues for users of HIV pre-exposure prophylaxis, survey finds

A new survey finds that men who would be potential users of HIV pre-exposure prophylaxis (PrEP) medication prefer long-acting injections over pills, but rank side effects and costs as the most important issues for them in considering whether to take PrEP.

1 Feb 2023